CDRD Ventures Inc.

CDRD Ventures Inc.
The Centre for Drug Research and Development

The Centre for Drug Research and Development
Kairos Therapeutics Inc.

Kairos Therapeutics Inc.

December 12, 2013 11:00 ET

CDRD Ventures Inc. of Vancouver, Canada Launches New Spin-off, Kairos Therapeutics

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 12, 2013) - CDRD Ventures Inc. (CVI), the commercialization vehicle of The Centre for Drug Research and Development (CDRD), announced today the launch of a new spin-off company, Kairos Therapeutics Inc., a biotechnology company developing next-generation antibody-drug conjugate (ADC) therapeutics for cancer. CDRD's Vice-President, Biologics, John Babcook, has been named President and Chief Scientific Officer of Kairos.

Kairos Therapeutics is developing a family of antibody-drug conjugate therapeutics based on a proprietary toxin and linker platform. ADCs are a highly-effective new class of targeted cancer therapeutics. The ADC platform will be available to potential partners wishing to access next-generation ADC technology. Kairos is also developing an internal pipeline of ADCs for the treatment of various forms of cancer. Proprietary site-specific conjugation methodology has been developed to maintain target affinity, effector function, and increase circulation half-life. The technology was developed in-house at CDRD and has been exclusively licensed to Kairos from CVI.

Preclinical efficacy has been established demonstrating an advantage over the leading FDA-approved HER2-based ADC, in two HER2+ cancer xenograft models. Further pre-clinical studies demonstrate that Kairos' ADCs are well-tolerated and stable. Through key partnerships, Kairos has access to several novel oncology targets and tumour-targeting ADCs for in-house development.

Kairos President and CSO, John Babcook, commented, "We believe we have developed a superior antibody-drug conjugate platform which in studies, so far, is showing advantages over leading ADC platforms. Our proprietary toxin and linker platform shows promise in the development of multiple treatments targeting several different cancers."

CVI President and CEO Ms. Natalie Dakers stated, "John Babcook is a pioneer in the development of therapeutic antibody programs, and he has an impressive record in the development of antibody-drug conjugates. We are excited to launch Kairos, and confident in the commercial potential of this ADC platform and the value it could bring to potential partners seeking strong linker and toxin technology."

Ms. Karimah Es Sabar, President and CEO of CDRD commented, "Kairos Therapeutics' ADC platform was discovered, developed and validated at CDRD. The launch of Kairos is the result of the world-class innovation and translation being conducted at CDRD, and highlights the value of a national centre where multiple levels of government and industry come together, and the tangible commercial outcomes that can result.

About Kairos Therapeutics Inc.

Kairos Therapeutics is developing next-generation antibody-drug conjugate (ADC) therapeutics for cancer. Through an exclusive license from CDRD Ventures Inc. (CVI), the commercialization vehicle of The Centre for Drug Research and Development (CDRD), Kairos is developing a suite of ADC therapeutics based on their proprietary toxin and linker platform. Preclinical efficacy has been established demonstrating superiority over the leading FDA-approved HER2-based ADC, in two HER2+ cancer xenograft models. Kairos is a spin-off company of CVI. For more information, visit www.kairostherapeutics.com.

About John Babcook

John Babcook is the founding President and Chief Scientific Officer of Kairos Therapeutics, and is also Vice President, Biologics at CDRD, and an Adjunct Professor of Molecular Biology and Biochemistry at Simon Fraser University. For more than 20 years, John has made significant contributions to the international biotechnology industry. While working at Amgen, Abgenix and ImmGenics and through collaborations with AstraZeneca, Pfizer, Abbott, Abbott Bioscience, Millennium, CellTech, Curagen, Corixa, Agensys, Progenics and The Scripps Research Institute, he has participated in the development of over 100 therapeutic antibody programs. Six therapeutic antibodies developed by him and his team are now in the clinic, including three antibody-drug conjugates.

About CDRD Ventures Inc. (CVI)

CVI is the commercialization vehicle of The Centre for Drug Research and Development (CDRD). With a first right to negotiate for any of the technologies developed at CDRD, CVI has a continuous and unparalleled pipeline of the most innovative and commercially-promising pre-validated and thus de-risked technologies in Canada. From CDRD's drug development projects and/or external opportunities, CVI licenses select promising technologies with the goal to further advance them to a stage where they can attract licensing partners, form the foundation for a new spin-off company, or secure the investment needed for clinical development. www.cdrdventures.com

About The Centre for Drug Research and Development (CDRD)

CDRD is Canada's fully-integrated national drug development and commercialization centre, providing expertise and infrastructure to enable researchers from leading health research institutions to advance promising early-stage drug candidates. Its mandate is to de-risk discoveries stemming from publicly-funded health research and transform them into viable investment opportunities for the private sector - thus successfully bridging the commercialization gap between academia and industry, and translating research discoveries into new therapies for patients. Canada's Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR). www.cdrd.ca

Contact Information